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Abstract
Context: Violence towards others is a seldom-studied adverse drug event and an atypical one because the risk of injury
extends to others.
Objective: To identify the primary suspects in adverse drug event reports describing thoughts or acts of violence towards
others, and assess the strength of the association.
Methodology: From the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) data, we extracted all
serious adverse event reports for drugs with 200 or more cases received from 2004 through September 2009. We identified
any case report indicating homicide, homicidal ideation, physical assault, physical abuse or violence related symptoms.
Main Outcome Measures: Disproportionality in reporting was defined as a) 5 or more violence case reports, b) at least twice
the number of reports expected given the volume of overall reports for that drug, c) a x2 statistic indicating the violence
cases were unlikely to have occurred by chance (p,0.01).
Results: We identified 1527 cases of violence disproportionally reported for 31 drugs. Primary suspect drugs included
varenicline (an aid to smoking cessation), 11 antidepressants, 6 sedative/hypnotics and 3 drugs for attention deficit
hyperactivity disorder. The evidence of an association was weaker and mixed for antipsychotic drugs and absent for all but 1
anticonvulsant/mood stabilizer. Two or fewer violence cases were reported for 435/484 (84.7%) of all evaluable drugs
suggesting that an association with this adverse event is unlikely for these drugs.
Conclusions: Acts of violence towards others are a genuine and serious adverse drug event associated with a relatively
small group of drugs. Varenicline, which increases the availability of dopamine, and antidepressants with serotonergic
effects were the most strongly and consistently implicated drugs. Prospective studies to evaluate systematically this side
effect are needed to establish the incidence, confirm differences among drugs and identify additional common features.
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Introduction
Violent thoughts and acts towards others area common
occurrence in our society but rarely studied as an adverse drug
event. Increased risk of suicidal behaviors—but not violence—
associated with antidepressants has been examined through meta-
analysis of clinical trials for approval by the U.S. Food and Drug
Administration. [1,2]
Despite limited clinical study, numerous drugs contain FDA-
required warnings to doctors or patients about the possibility of
aggressive or violent acts. Among the drugs with warnings about
aggressive behaviors are varenicline, zolpidem, montelukast, and
all antidepressant drugs. [3–6] The mandatory patient Medication
Guide for varenicline, the antidepressants and quetiapine warn
patients to contact a healthcare provider immediately if they start
‘‘acting aggressive, being angry or violent.’’ [3,7–9]
In this study we summarize and evaluate the evidence about
reported acts of violence associated with therapeutic drugs among
all serious adverse drug events reported to the FDA from 2004
through the third quarter of 2009.
Methods
The cases for this study were selected from the Institute for Safe
Medication Practices (ISMP) QuarterWatch database of all
adverse drug events reported to the FDA since 1968. [10] The
FDA publishes for research use computer extracts of all adverse
drug event reports that it receives, [11] and all such cases are
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medical professionals as ‘‘MedWatch Reports,’’ the FDA’s adverse
event database also includes serious foreign cases from international
drug companies who market the drugs in the United States. We
limited this study to cases with serious outcome as defined by the
FDA, and which includes death, disability, hospitalization, a life
threatening event, an event that required medical intervention to
prevent harm, or other medically serious conditions. The latest
version of all cases with an initial report date from 2004 through the
third quarter of 2009 was included. To qualify for inclusion in this
study as an evaluable drug, it had to have wide enough clinical use
and sufficient post marketing surveillance to have generated 200 or
more case reports for any serious adverse event in the study period.
Drug names were standardized from the QuarterWatch dictionary,
which is in turn based on standardized ingredient names in the
National Library of Medicine RxNorm database. [12]
Identification of Violence Reports
In the published computer extracts, the adverse event narrative
description is replaced by one or more standardized medical terms
selected from Version 11.1 of the Medical Dictionary for
Regulatory Affairs (MedDRA). [13] We defined a violence event
as any case report containing one or more of the following
MedDRA terms: Homicide, Physical assault, Physical abuse,
Homicidal ideation or Violence-related symptom. If a case report
contained more than one of these terms, it was assigned to the most
severe event term in the order listed above. In selecting terms from
the MedDRA dictionary, we sacrificed some degree of sensitivity in
case identification to achieve greater specificity. Thus, from the
High Level Term group ‘‘Criminal Activity’’ we selected Homicide
and Physical assault but omitted more ambiguous descriptors such
as ‘‘Crime’’ or ‘‘Spousal Abuse.’’ Similarly from the High Level
Term group Behavioral and Social Disturbances we selected
Violence-related Symptom and Homicidal ideation but omitted
the more general terms Aggression, Belligerence and Hostility. To
assure an accurate count of widely used drugs for which no violence
cases were reported we included all evaluable drugs in our data set.
Proportional Reporting Ratio
The null hypothesis for this study assumed that a violence case
could be attributed to a drug by pure chance, and that drugs with
a greater total number of adverse event reports might be exposed
to greater risk of accruing a violence case. A drug might have a
larger total number of adverse events reported for several reasons
unrelated to safety, including more widespread clinical use, a
higher reporting rate, the patient population treated, and more
extensive international sales by the pharmaceutical sponsor.
To assess the null hypothesis we calculated the proportional
reporting ratio (PRR) for each evaluable drug using the method of
Evans. [14] With this method we compare the proportion of
violence cases for each drug (drug violence events/all drug events)
to the proportion of all other violence events for all other evaluable
drugs (all other violence events/all other drugs events). For
example, violence cases accounted for 35/3689 (0.95%) of all cases
for the drug bupropion. For all the other drugs, violence cases
accounted for 1902/776480 (0.2%) PRR=3.9. In other words,
the number of violence cases was 3.9 times greater for bupropion
than for all other drugs combined after adjusting for the volume of
reports. Using the x
2 test for independence, we assessed the
strength of the relationship, and the probability that that the PRR
could have occurred by chance. In the bupropion example,
x
2=70.6 df=1 p,0.01. To allow for the fact that some drugs
might have as few as 5 index cases we applied the Yates correction
to the x
2 statistic.
Study Criteria
To be identified as disproportionally associated with violence
cases, an evaluable drug had to have a PRR$2, a x
2$4.0, and 5
or more violence cases attributed. These are the Evans criteria
except that our minimum threshold was 5 cases rather than the 3
cases specified in Evans. As a practical matter a x
2$4 with 1
degree of freedom produces a sample estimate with p,0.01 but p
values are provided to assess borderline cases.
The data for this study were maintained in an open source
MySQL database (Oracle, www.mysql.com) and analyzed with
open source software from the R-Project for Statistical Computing
(www.r-project.org), version 2-11-0.
Results
In the 69-month reporting period we identified 484 evaluable
drugsthataccounted for 780,169serious adverseeventreports ofall
kinds. This total included 1,937 (0.25%) cases meeting the violence
criteria. The violence cases included 387 reports of homicide, 404
physical assaults, 27 cases indicating physical abuse, 896 homicidal
ideation reports, and 223 cases described as violence-related
symptoms. The patients were 41% female and 59% male with a
mean age of 36 years (SD=17.9) Consumers reported 651/1937
(38%) of the cases, foreign and domestic health professionals were
the source for 967/1937 (49.9%) and the remainder were missing
(217), from lawyers (67) or clinical studies (34).
Drugs Identified
Among 484 evaluable drugs, 31 drugs met the study criteria for
a disproportionate association with violence, and accounted for
1527/1937 (79%) of the violence cases. The drugs are listed in
Table 1. They include varenicline (a smoking cessation aid), 11
antidepressant drugs, 3 drugs for attention deficit hyperactivity
disorder, and 5 hypnotic/sedatives. No violence cases were
reported for 324/484 (66.9%) of all evaluable drugs, and 1 or 2
cases were reported for an additional 86/484 (17.8%). Thus, for
84.7% of all evaluable drugs in widespread clinical use, an
association with violence appeared highly unlikely.
Smoking Cessation
Table 2 shows the results for three drugs available as an aid to
smoking cessation programs: varenicline, bupropion and nicotine
replacement products. Bupropion is indicated for both depression
and as an aid to smoking cessation, so those results are not limited
to the smoking cessation population. Varenicline has the largest
number of reported violence cases, the highest proportion of
violence cases (PRR=18.0) and the highest x2 statistic (x2=5172
df=1 p,0.01) of any of the 484 evaluable drugs. Comparing
reports of violence in the patient population seeking to discontinue
smoking provides adjustment for the possibility that the side effects
might be caused by stopping smoking rather than the drug.
Psychoactive Drugs
Since psychoactive drugs accounted for most of the drugs
identified we further analyzed them by class, including other drugs
in the class that did not meet the criteria for an association. The
results by drug class are shown in Table 3. These data indicate
marked differences between drug classes. All the antidepressants
were associated with violence cases, except for two tricyclics,
trazodone and amitriptyline, which had a similarly elevated PRR
that was statistically significant, but fewer than 5 required cases to
qualify as suspect under our criteria. The PRR for all
antidepressants combined was 8.4, higher than for any other class
of psychoactive drugs. At the other extreme, mood stabilizers/
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levetiracetam and overall the group did not indicate an elevated
risk. Results for the antipsychotics were mixed, ranging from a
PRR=4.2 for aripiprazole to a low of PRR=0.6 for clozapine
indicating fewer than expected reports (x 2=1.6 p=0.203).
Grouped together the antipsychotics were borderline with a PRR
of 1.9, slightly less than the 2.0 required, and x2=68.5 p,0.01.
The results for hypnotics/sedatives were also mixed with strong
signals for zolpidem and triazolam, and little or no evidence for
Table 1. Drugs associated with violence adverse drug events.
Drug Name PRR* x2 (df=1) P Value
Violence
Cases
VARENICLINE 18.0 5172.0 p,0.01 408
FLUOXETINE 10.9 615.7 p,0.01 72
PAROXETINE 10.3 1353.2 p,0.01 177
AMPHETAMINES 9.6 227.7 p,0.01 31
MEFLOQUINE 9.5 67.2 p,0.01 10
ATOMOXETINE 9.0 339.5 p,0.01 50
TRIAZOLAM 8.7 40.3 p,0.01 7
FLUVOXAMINE 8.4 25.8 p,0.01 5
VENLAFAXINE 8.3 517.2 p,0.01 85
DESVENLAFAXINE 7.9 41.4 p,0.01 8
MONTELUKAST 7.0 260.8 p,0.01 53
SERTRALINE 6.7 297.4 p,0.01 64
ZOLPIDEM 6.7 222.1 p,0.01 48
ESCITALOPRAM 5.0 94.0 p,0.01 31
SODIUM OXYBATE 4.9 15.0 p,0.01 6
CITALOPRAM 4.3 83.1 p,0.01 34
ARIPIPRAZOLE 4.2 51.6 p,0.01 23
OXYCODONE 4.1 104.4 p,0.01 46
BUPROPION 3.9 70.6 p,0.01 35
ZIPRASIDONE 3.8 36.7 p,0.01 19
METHYLPHENIDATE 3.6 48.5 p,0.01 27
MIRTAZAPINE 3.4 22.4 p,0.01 15
GABAPENTIN 3.3 53.8 p,0.01 35
LEVETIRACETAM 3.3 30.3 p,0.01 21
DIAZEPAM 3.1 13.7 p,0.01 11
ALPRAZOLAM 3.0 17.5 p,0.01 15
DULOXETINE 2.8 49.7 p,0.01 45
CLONAZEPAM 2.8 9.5 p,0.01 10
INTERFERON ALFA 2.7 56.7 p,0.01 54
RISPERIDONE 2.2 16.6 p,0.01 29
QUETIAPINE 2.0 25.8 p,0.01 53
*Proportional Reporting Ratio.
doi:10.1371/journal.pone.0015337.t001
Table 2. Drugs prescribed for smoking cessation.
Drug Name PRR* x2 P Value Violence Cases All Cases
VARENICLINE 18.0 5172 p,0.01 408 11393
BUPROPION** 3.9 70.6 p,0.01 35 3689
NICOTINE 1.9 3.6 p=0.059 11 2383
*Proportional Reporting Ratio.
**All indications of this antidepressant drug.
doi:10.1371/journal.pone.0015337.t002
Table 3. Psychoactive drugs by drug class and association
with violence.*
Drug Class/Drug PRR x2 P Value Violence All Cause
Antidepressants 8.4 2956.3 p,0.01 578 37632
FLUOXETINE 10.9 615.7 p,0.01 72 2752
PAROXETINE 10.3 1353.2 p,0.01 177 7508
FLUVOXAMINE 8.4 25.8 p,0.01 5 239
VENLAFAXINE 8.3 517.2 p,0.01 85 4283
DESVENLAFAXINE 7.9 41.4 p,0.01 8 410
SERTRALINE 6.7 297.4 p,0.01 64 3938
ESCITALOPRAM 5.0 94 p,0.01 31 2529
CITALOPRAM 4.3 83.1 p,0.01 34 3192
AMITRIPTYLINE 4.2 4.5 p=0.033 3 286
BUPROPION 3.9 70.6 p,0.01 35 3689
TRAZODONE 3.5 4.9 p=0.026 4 457
MIRTAZAPINE 3.4 22.4 p,0.01 15 1810
DULOXETINE 2.8 49.7 p,0.01 45 6539
Attention deficit
hyperactivity
6.9 509.4 p,0.01 108 6627
AMPHETAMINES 9.6 227.7 p,0.01 31 1317
ATOMOXETINE 9.0 339.5 p,0.01 50 2290
METHYLPHENIDATE 3.6 48.5 p,0.01 27 3020
Mood Stabilizer/
Anticonvulsant
1.1 0.3 p=0.585 60 22346
LEVETIRACETAM 3.3 30.3 p,0.01 21 2619
OXCARBAZEPINE 1.4 0.2 p=0.673 5 1487
TOPIRAMATE 1.3 0.4 p=0.505 9 2727
LAMOTRIGINE 0.8 0.2 p=0.658 11 5275
VALPROIC ACID 0.8 0.1 p=0.735 8 3843
PHENYTOIN 0.4 1.7 p=0.19 3 2795
CARBAMAZEPINE 0.3 3.3 p=0.068 3 3600
Antipsychotic 1.9 68.5 p,0.01 167 36225
ARIPIPRAZOLE 4.2 51.6 p,0.01 23 2248
ZIPRASIDONE 3.8 36.7 p,0.01 19 2012
RISPERIDONE 2.2 16.6 p,0.01 29 5464
QUETIAPINE 2.0 25.8 p,0.01 53 10696
OLANZAPINE 1.6 5.4 p=0.02 30 7781
PALIPERIDONE 0.7 0.2 p=0.653 3 1790
CLOZAPINE 0.6 1.6 p=0.203 10 6234
Hypnotic/Sedative 3.9 68.5 p,0.01 97 10279
TRIAZOLAM 8.7 40.3 p,0.01 7 325
ZOLPIDEM 6.7 222.1 p,0.01 48 2947
ESZOPICLONE 4.9 8.8 p,0.01 4 331
DIAZEPAM 3.1 13.7 p,0.01 11 1427
ALPRAZOLAM 3.0 17.5 p,0.01 15 2049
CLONAZEPAM 2.8 9.5 p,0.01 10 1462
MIDAZOLAM 1.4 0 NA 1 292
LORAZEPAM 0.3 1.2 p=0.269 1 1446
*Drugs associated with violence reports in Table 1 are in bold face.
doi:10.1371/journal.pone.0015337.t003
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showed an association.
Discussion
These data show that serious acts of violence towards others
were regularly reported as an adverse drug event, and that marked
differences were observed among drugs. Varenicline had the
strongest association with violence by every measure used in this
study. In addition, antidepressant drugs showed consistently
elevated risk, even when compared with antipsychotics and mood
stabilizers, which are used in psychiatric patients populations in
which violent acts may occur. Violence cases as defined here were
infrequently reported, accounting for 0.25% of all serious adverse
drug events, and confined to a relatively small number of drugs.
This analysis shares many limitations common to studies based
on spontaneously reported adverse drug events. The submission of
an individual adverse event report does not itself establish
causality, only that a reporting individual suspected a relationship
existed. However, such reports frequently contribute to a broader
assessment of causality. In the computer excerpts, the narrative
description of each event is replaced by a series of standardized
medical terms, as are adverse events in clinical studies. The quality
and detail in each report varies, and the reporting rate for adverse
drug events is unknown and believed to vary among types of event,
among drugs and over periods of time. [15]
This study, however, contains numerous features intended to
minimize the limitations of adverse event data from postmarketing
surveillance. The proportional reporting ratio takes into account
two possibilities: a) that wider use or a higher reporting rate
exposes a drug to a greater chance of having a violence case
attributed, and b) that a higher number of reports might have
occurred by chance. The varying results among drugs for smoking
cessation and the mood stabilizers show it is unlikely that the
violence events are attributed to existing problems in the patient
populations treated. Also, the focus of this study was on specific
event terms that unequivocally described a violent act or thought –
such as homicide or physical assault. By excluding more general
adverse event terms such as ‘‘aggression’’ or ‘‘anger’’ many
thousands of less specific cases were eliminated under the study
criteria. While this means that the study did not count many
possible cases of violence towards others (a loss of sensitivity) the
restrictive criteria increased specificity. However, given that
violent thoughts or actions are not typically attributed to drug
therapy or recorded in medical records, the reporting rate for
violence cases could be very low. The selected violence cases do
not provide a reliable estimate of how often they might occur.
Common and Unusual Features
These events were reported in a patient population that was
41% female and one-half older than age 36. In addition a majority
of reports were submitted either by health professionals (primarily
MDs) or from foreign sources where reporting is normally limited
to health professionals.
While the reported events occurred among drugs used in widely
different patient populations, the list of suspects was dominated by
drugs that increase the availability of serotonin or dopamine in the
brain. Most of the antidepressants increase the availability of
serotonin through reuptake inhibition. Varenicline increases the
availability of dopamine through partial antagonism of acetylcho-
line nicotinic receptors. [16] Sodium oxybate is a dopamine
agonist indicated for narcolepsy. [17] Amphetamines increase
concentrations of dopamine and serotonin. [18] On the other
hand, no signal was seen for many common mood stabilizers such
valproic acid, carbamazepine, and phenytoin, even though these
drugs are used in bipolar patients who may experience psychosis in
the acute manic phase and therefore be more prone to violence.
The proportional reporting ratio—our primary measure of
elevated risk—showed consistency among drugs with the most
similar mechanisms of action. As shown in Table 3, for example,
venlafaxine had a PRR of 8.3 and desvenlafaxine a PRR of 7.9
even though the number of total cases and violence cases were
different. Similarly citalopram had a PRR of 4.3 and escitalopram
a PRR of 5.0. We believe it is also noteworthy that no signal
whatever was seen for an overwhelming majority of drugs.
Additional Questions for Study
We have previously examined varenicline’s association with
serious psychiatric symptoms including aggression/violence. [19–
22] The aggression/violence case series for varenicline was
consistent with these data but revealed other features that may
or may not occur in cases attributed to other drugs. These features
include early onset of psychiatric symptoms (usually within a few
days), a senseless act of aggression/violence directed at anyone
who happened to be near by, and resolution of the symptoms upon
discontinuation. A more detailed case series of several hundred
cases involving different classes of drugs would greatly improve
scientific understanding of this drug adverse event and possibly
lead the way towards identifying an at-risk patient population.
Conclusions
These data provide new evidence that acts of violence towards
others are a genuine and serious adverse drug event that is
associated with a relatively small group of drugs. Varenicline,
which increases the availability of dopamine, and serotonin
reuptake inhibitors were the most strongly and consistently
implicated drugs. Prospective studies to evaluate systematically
this side effect are needed to establish the incidence, confirm
differences among drugs and identify additional common features.
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